BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28205194)

  • 1. Novel and Expanded Oncology Drug Approvals of 2016-PART 2: New Options in the Management of Hematologic Malignancies.
    Knepper TC; Saller J; Walko CM
    Oncology (Williston Park); 2017 Feb; 31(2):138-46. PubMed ID: 28205194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel and Expanded Oncology Drug Approvals of 2016-PART 1: New Options in Solid Tumor Management.
    Knepper TC; Saller J; Walko CM
    Oncology (Williston Park); 2017 Feb; 31(2):110-21. PubMed ID: 28205191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
    Olin JL; Griffiths CL; Smith MB
    J Oncol Pharm Pract; 2018 Oct; 24(7):517-524. PubMed ID: 28696175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
    Huang LW; Wong SW; Andreadis C; Olin RL
    Curr Oncol Rep; 2019 Mar; 21(4):35. PubMed ID: 30848394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy for hematologic malignancies.
    Kuriakose P
    Cancer Control; 2005 Apr; 12(2):82-90. PubMed ID: 15855891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
    Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
    Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
    Rao AV; Schmader K
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):247-62. PubMed ID: 17996665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B-Cell Malignancies: The Use of Small Molecule Agents for Treatment and Management.
    Rogers BB
    Clin J Oncol Nurs; 2020 Apr; 24(2):199-204. PubMed ID: 32196006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meaningful endpoints for therapies approved for hematologic malignancies.
    Smith BD; DeZern AE; Bastian AW; Durie BGM
    Cancer; 2017 May; 123(10):1689-1694. PubMed ID: 28222220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.
    Gupta IV; Jewell RC
    Ann N Y Acad Sci; 2012 Aug; 1263():43-56. PubMed ID: 22830942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.
    Howard SC; Trifilio S; Gregory TK; Baxter N; McBride A
    Ann Hematol; 2016 Mar; 95(4):563-73. PubMed ID: 26758269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustine in the treatment of hematologic malignancies. Introduction.
    Diehl V; Cheson BD
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):1-3. PubMed ID: 12170424
    [No Abstract]   [Full Text] [Related]  

  • 14. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
    Nightingale G
    Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obinutuzumab for the treatment of chronic lymphocytic leukemia.
    Rogers KA; Jones JA
    Drugs Today (Barc); 2014 Jun; 50(6):407-19. PubMed ID: 24983589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hematologic Malignancies/Pediatric Malignancies. Roles of Drugs Approved as New Agents and as Additional Indications for Relapse or Refractory Hematologic Malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2016 May; 43(5):528-9. PubMed ID: 27344679
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
    Klein C; Bacac M; Umana P; Fingerle-Rowson G
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
    Kurtz SE; Eide CA; Kaempf A; Khanna V; Savage SL; Rofelty A; English I; Ho H; Pandya R; Bolosky WJ; Poon H; Deininger MW; Collins R; Swords RT; Watts J; Pollyea DA; Medeiros BC; Traer E; Tognon CE; Mori M; Druker BJ; Tyner JW
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):E7554-E7563. PubMed ID: 28784769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 50th Annual Meeting of the American Society of Hematology.
    Cunningham S; Muneer S
    Clin Lymphoma Myeloma; 2009 Jun; 9(3):197-205. PubMed ID: 19525188
    [No Abstract]   [Full Text] [Related]  

  • 20. Balancing patient value and payer cost in hematologic malignancies: can it be done?
    Allen PB; Flowers CR
    Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):123-126. PubMed ID: 29486601
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.